Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyLetter

Pauling and Frech reply

JOHN D. PAULING and TRACY M. FRECH
The Journal of Rheumatology November 2019, 46 (11) 1544-1545; DOI: https://doi.org/10.3899/jrheum.190565
JOHN D. PAULING
Royal National Hospital for Rheumatic Diseases (at Royal United Hospitals), and Department of Pharmacy and Pharmacology, University of Bath, Bath, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for JOHN D. PAULING
  • For correspondence: JohnPauling@nhs.net
TRACY M. FRECH
University of Utah and Salt Lake Regional Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for TRACY M. FRECH
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We thank Dr. Hughes for his interest1 in our article2 reporting factors influencing Raynaud phenomenon (RP) symptom reporting in patients with systemic sclerosis (SSc). We presented data demonstrating differences in Raynaud symptom reporting using the Raynaud Condition Score (RCS) diary depending on season of enrollment2. A weaker-than-expected relationship between external temperature (using Meterological Office data) and contemporaneous collection of the RCS diary (Spearman ρ ∼ −0.25) suggests that other factors beyond cold exposure may contribute to Raynaud burden in SSc2. Dr. Hughes has presented an analysis of the effect of season on Raynaud by evaluating the influence of seasonal variation on Internet searches using the term “Raynaud phenomenon”. Consistent with an anticipated relationship between cold exposure and Raynaud symptoms, a clear pattern emerges highlighting increasing health-seeking Internet search activity for Raynaud during the colder months, with troughs during warmer seasons. An evaluation of mean monthly UK temperatures over the same period of analysis suggests seasonal factors beyond external temperature may contribute to information-seeking behavior for Raynaud symptoms. The chart of UK Internet search activity for RP presented by Dr. Hughes revealed a pronounced spike during January 2008 (> 70 “peak popularity” units) compared to January 2010 (< 40 units), despite average UK temperatures within those months being 5.3°C and 0.9°C, respectively (Figure 1)3. Seasonal factors beyond external temperature may therefore contribute to variation in RP symptoms (and information-seeking Internet searches), perhaps including humidity, precipitation, and wind chill factor. A range of factors beyond cold exposure has been associated with precipitating RP symptoms in SSc, particularly situations associated with temperature change (e.g., entering air-conditioned premises, damp/water exposure, chilled food aisles in grocery stores), and emotional stress4,5. Extreme cold can lead to reluctance to go outdoors and increased reliance upon others, which could mitigate RP symptoms (at the expense of reduced social participation)4.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Monthly UK mean temperatures 2004–present (degrees C), using UK meteorological data available from the Meteorological Office UK and regional series datasets3.

It is expected that the majority of the Internet searches presented by Dr. Hughes will have been made by people affected by “primary RP.” Once again, there are expected (and unexpected) associations between local climate and Raynaud symptoms. There is marked geographic variation in prevalence estimates of primary RP across different countries, ranging from 2.1% of females in Japan, to 22.4% in Scandinavia6. Such variation is typically attributed to differences in climate and considered in the context of digital vasoconstriction representing an important, and entirely appropriate, thermoregulatory response to cold exposure. Such observations have led people to question the very existence of primary RP, proposing instead that “these are healthy people whose cold and colourful hands are more obvious (and) occasionally more troublesome, than that of their peers”7. Additional cultural and social (and possibly ethnic) factors may also influence the relationship between climate and Raynaud symptoms. Community-based studies in South Carolina and 4 geographic regions of France supported a direct relationship between local climate and RP prevalence, but this relationship was challenged by the subsequent identification of a comparatively lower prevalence of RP symptoms in southern Estonia despite its colder winters7,8,9. Cultural, ethnic, and clinical phenotypic factors appear to contribute to geographic variation in RP symptom burden in SSc. Data from separate clinical trials of tadalafil for SSc-RP that each enrolled patients in winter identified a higher frequency and burden of RP symptoms in patients enrolled in Lucknow, India (mean 3.5 Raynaud attacks/day and mean daily RCS of 5.28/10) compared to Ann Arbor, Michigan (2.9 attacks/day and mean RCS 3.76/10), despite an expected difference in mean daily temperature of ∼20°C (+16°C to −4°C) across the 2 regions10.

What are the implications of such observations for clinical practice and therapeutic trials of RP? The relationship between climate and geographic variation in RP prevalence highlights the importance of maintaining core temperature when counseling patients on RP management. Reassuring patients with primary RP that digital vasoconstriction is an important physiological response and that, for many, RP symptoms represent an exaggerated healthy state that, while intrusive, are not dangerous may allay health anxiety. Therapeutic trials have traditionally enrolled patients over the winter months, but 12- to 16-week assessments of primary endpoints risk seasonal variation in weather influencing outcome assessments — a somewhat overlooked factor that may contribute to the high placebo response typically observed in RP clinical trials10. We agree with Dr. Hughes’ suggestion that shorter-term clinical trials over 1–2 weeks are preferable, but only if outcome measures can be validated to facilitate this (e.g., objective microvascular imaging or retrospective self-administered patient-reported outcome instruments)10. Weather (certainly across much of Europe and North America) can be fickle, with frequent swift and marked variations that could influence the findings of RP clinical trials (Figure 2). It is perhaps impossible to entirely mitigate the effect of weather when evaluating RP, but understanding its contribution can aid interpretation of study findings and help optimize clinical trial design.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Short-term marked variation in local weather could greatly influence Raynaud phenomenon clinical trial outcomes. A. The University of Bath campus, February 1, 2019 (−2°C), and (B) the same location on February 27, 2019 (+16°C).

REFERENCES

  1. 1.↵
    1. Hughes M
    . Effect of season on Internet searches for information on Raynaud phenomenon. J Rheumatol 2019;46:1543–4.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Pauling JD,
    2. Reilly E,
    3. Smith T,
    4. Frech TM
    . Factors influencing Raynaud condition score diary outcomes in systemic sclerosis. J Rheumatol 2019 May 15 (E-pub ahead of print).
  3. 3.↵
    Meterological Office UK and regional series datasets, 2019. [Internet. Accessed June 6, 2019.] Available from: www.metoffice.gov.uk/pub/data/weather/uk/climate/datasets/Tmean/date/UK.txt
  4. 4.↵
    1. Pauling JD,
    2. Domsic RT,
    3. Saketkoo LA,
    4. Almeida C,
    5. Withey J,
    6. Jay H,
    7. et al.
    Multinational qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis. Arthritis Care Res 2018;70:1373–84.
    OpenUrl
  5. 5.↵
    1. Pauling JD,
    2. Saketkoo LA,
    3. Matucci-Cerinic M,
    4. Ingegnoli F,
    5. Khanna D
    . The patient experience of Raynaud’s phenomenon in systemic sclerosis. Rheumatology 2019;58:18–26.
    OpenUrl
  6. 6.↵
    1. Garner R,
    2. Kumari R,
    3. Lanyon P,
    4. Doherty M,
    5. Zhang W
    . Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 2015;5:e006389.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hadler NM
    . “Primary Raynaud’s” is not a disease or even a disorder; it’s a trait. J Rheumatol 1998;25:2291–4.
    OpenUrlPubMed
  8. 8.↵
    1. Maricq HR,
    2. Carpentier PH,
    3. Weinrich MC,
    4. Keil JE,
    5. Palesch Y,
    6. Biro C,
    7. et al.
    Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol 1997;24:879–89.
    OpenUrlPubMed
  9. 9.↵
    1. Valter I,
    2. Maricq HR
    . Prevalence of Raynaud phenomenon in Tartu and Tartumaa, southern Estonia. Scand J Rheumatol 1997;26:117–24.
    OpenUrlPubMed
  10. 10.↵
    1. Pauling JD,
    2. Nagaraja V,
    3. Khanna D
    . Insight into the contrasting findings of therapeutic trials of digital ischaemic manifestations of systemic sclerosis. Curr Treatm Opt Rheumatol 2019;5:85–103.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 11
1 Nov 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pauling and Frech reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pauling and Frech reply
JOHN D. PAULING, TRACY M. FRECH
The Journal of Rheumatology Nov 2019, 46 (11) 1544-1545; DOI: 10.3899/jrheum.190565

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Pauling and Frech reply
JOHN D. PAULING, TRACY M. FRECH
The Journal of Rheumatology Nov 2019, 46 (11) 1544-1545; DOI: 10.3899/jrheum.190565
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire